<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01427868</url>
  </required_header>
  <id_info>
    <org_study_id>LG-BVCL009</org_study_id>
    <nct_id>NCT01427868</nct_id>
  </id_info>
  <brief_title>Bioequivalence of LB80380 Free Base and Maleate Salt Tablets</brief_title>
  <official_title>An Open-label, Phase I Study in Healthy Male Subjects to Compare the Pharmacokinetics of LB80331 and LB80317, Metabolites of LB80380, After a Single Oral Administration of LB80380 Free Base 150 mg (60 mg + 90 mg) Tablet or LB80380 Maleate Tablet 183 mg (150 mg as a Free Base)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LG Life Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LG Life Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is to compare pharmacokinetics of LB80331 and LB80317, which are the metabolites of
      LB80380, after a single oral administration of LB80380 free base 150 mg (60 mg + 90 mg)
      tablet or LB80380 maleate tablet 183 mg (150 mg as a free base) in healthy male subjects.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">November 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>AUC</measure>
    <time_frame>up to 144 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Cmax</measure>
    <time_frame>up to 144 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants with Adverse Events and Number of Adverse Events as a Measure of Safety and tolerability</measure>
    <time_frame>up to 7 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Profile of Pharmacokinetics</measure>
    <time_frame>up to 144 hours</time_frame>
    <description>Tmax, Aet, CL/F</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>Hepatitis B</condition>
  <arm_group>
    <arm_group_label>LB80380 maleat salt</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>LB80380 free base</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LB80380 maleate salt</intervention_name>
    <description>183 mg (150 mg as a free base)</description>
    <arm_group_label>LB80380 maleat salt</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LB80380 free base</intervention_name>
    <description>150 mg</description>
    <arm_group_label>LB80380 free base</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male with good health

          -  20 to 45 years of age at screening

          -  Body weight Â±20% of ideal body weight

          -  Willingness and ability to comply with study procedures and communicate with
             investigators

          -  Provided written consent voluntarily after informed of all the pertinent aspects of
             the trial

        Exclusion Criteria:

          -  Clinically significant abnormality on medical interview, physical examination,
             electrocardiogram or clinical laboratory evaluations

          -  Clinically significant acute or chronic medical conditions

          -  Use of prescriptive medicine within 14 days, or over-the-counter drug within 7 days
             before the first day of drug administration

          -  Participation in clinical trial within 3 months before the first day of drug
             administration

          -  Alcohol abuse

          -  Habitual smoker

          -  Habitual user of herbal medicine

          -  Use of grapefruit-containing food or grapefruit juice during the study period

          -  Positive drug abuse test and Positive HBs-antigen, HCV-antibody, or HIV-antibody test
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wooseong Huh, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Samsung Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Trial Center, Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>September 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 25, 2011</study_first_submitted>
  <study_first_submitted_qc>September 1, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 2, 2011</study_first_posted>
  <last_update_submitted>September 1, 2011</last_update_submitted>
  <last_update_submitted_qc>September 1, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 2, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>LB80380</keyword>
  <keyword>bioequivalence</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis B</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Maleic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

